Potent and broad-spectrum antiviral activities against multiple SARS-CoV-2 variants including the original variant , Beta, Delta, Omicron BA.4 & BA.5, XBB variants, ect.
Excellent antiviral efficacy and safety profile, favorable lung tissue distribution in pre-clinical studies.
TAZOVID demonstrated excellent safety and efficacy in RCT Ph3 study with significant improvement in symptom recovery and viral load reduction.
The daily dosage is also the lowest among currently approved 3CL protease inhibitors.
Leads to formation of “empty” non-functional capsids, devoid of genetic material，and inhibits cccDNA formation in pre-clinical studies.
Demonstrated robust antiviral activities including HBV DNA and pgRNA in 28-day Phase 1b study in CHB patients.
A novel oral small-molecule inhibitor targeting HBsAg via inhibiting PAPD5/7 (Poly A tail polymerase-associated domain 5/7).
Reduces serum levels of HBsAg in HBV mouse models effectively.
Good PK, tolerability and safety profile in Ph1 SAD and MAD studies.
A novel 2nd generation oral small-molecule inhibitor targeting HBsAg via inhibiting PAPD5/7 (Poly A tail polymerase-associated domain 5/7).
Reduces serum levels of HBsAg in HBV mouse models effectively.
Pre-clinical evidence of anti-cancer activity was observed in CDX and PDX models for multiple solid tumors.
Completed Ph1a PK and safety evaluation.
Great efficacy achieved in Ph1b expansion cohorts in NSCLC patients.
Great efficacy demonstrated in pre-clinical studies in reducing liver fibrosis caused by NASH Also have potential to treat other fibrotic diseases including fibrosis induced by HBV infection and chemical-induced liver injury.
Excellent PK and safety profile in human Ph1 single ascending dose (SAD) study.
